worth a watch today.
in addition to the very strong revenue results which have yet to be factored into EYE share price US proposal for reimbursement changes to significantly benefit EYE came out last 24 hours.
sight sciences closest competitor (but with inferior device) up 20% in US trading
full details over on the EYE CMS reimbursement changes thread
- Forums
- ASX - Short Term Trading
- Short Term Trading Week Starting: 08 Jul
Short Term Trading Week Starting: 08 Jul, page-27
Featured News
Featured News
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online